SiBone (NASDAQ:SIBN) CEO Sells 75,000 Shares of Company Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 75,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $25.30, for a total transaction of $1,897,500.00. Following the completion of the transaction, the chief executive officer owned 304,256 shares in the company, valued at $7,697,676.80. This represents a 19.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30.
• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Trading Down 0.1%

Shares of SiBone stock traded down $0.03 during trading on Friday, reaching $24.24. 683,472 shares of the company were exchanged, compared to its average volume of 638,581. The business has a 50-day moving average price of $19.71 and a 200-day moving average price of $16.56. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -78.19 and a beta of 0.64. The company has a quick ratio of 7.55, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. The firm had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. Sell-side analysts anticipate that SiBone will post -0.34 EPS for the current fiscal year.

Institutional Investors Weigh In On SiBone

Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares in the last quarter. State of Wyoming boosted its holdings in shares of SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after buying an additional 4,490 shares during the period. Inceptionr LLC acquired a new position in shares of SiBone in the first quarter valued at approximately $156,000. ADAR1 Capital Management LLC bought a new stake in shares of SiBone during the first quarter worth $159,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of SiBone during the first quarter worth $204,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Needham & Company LLC cut their price target on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday. Truist Financial boosted their price objective on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. UBS Group upped their target price on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup reissued a “market outperform” rating on shares of SiBone in a research report on Tuesday. Finally, Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.